Phase 2 Stomach Cancer Trial, Recruiting NCT06395519 Sponsor: 858 Therapeutics, Inc. Condition: Stomach Cancer
Back to Stomach Cancer

Phase 2 Stomach Cancer Trial, Recruiting

NCT06395519
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are 18 years of age or older
  • You have been diagnosed with an advanced solid tumour cancer (one that has spread, cannot be removed by surgery, or has come back) that is not a brain tumour that started in the brain or spinal cord
  • Your cancer has gotten worse during or after your most recent cancer treatment, or you were unable to tolerate that treatment
  • Your cancer can be measured on scans, following standard measurement guidelines
  • You are generally well enough to carry out light activity and care for yourself (your doctor will assess this)
  • You have previously received standard approved treatments that were available to you, unless those treatments were not suitable or you chose not to have them
  • You have not taken part in another experimental drug trial within the past 3 weeks (or 5 half-lives of that drug, whichever is shorter, with a minimum of 2 weeks) before starting this trial
  • Your doctor expects you to live for at least 3 more months
  • Patients with a known BRCA2 gene mutation that stops the gene from working normally may be given extra consideration for joining

Who may not be able to join:

  • You are taking steroid tablets (such as prednisone) at a dose higher than 10 mg per day on an ongoing basis (low-dose steroids for a medical condition, or inhaled, skin, or eye steroids are generally allowed)
  • You have had full-dose radiotherapy within the last 6 weeks, or lower-dose (palliative) radiotherapy within the last 2 weeks
  • You have brain tumour spread (metastases) that are causing symptoms or getting worse — stable, previously treated brain metastases may be allowed if they have not changed for at least 4 weeks
  • You have a digestive system condition that could affect how your body absorbs the study drug, or you have had a bowel blockage in the last 6 months, or fluid drained from your abdomen within the last 8 weeks
  • You have spreading cancer in the membranes around the brain or spinal cord (leptomeningeal disease) that is active and worsening (confirm with trial site)
  • You have certain heart rhythm abnormalities detected on an ECG, a personal or family history of a specific inherited heart condition (long QT syndrome), are taking medications known to affect heart rhythm, or have other heart rhythm risk factors (confirm with trial site)
  • You have had a heart attack or unstable chest pain within the last 6 months, or have significant heart problems such as uncontrolled high blood pressure or heart failure
  • You have an active or long-term serious infection, including tuberculosis, hepatitis B, hepatitis C, or HIV-related illness — some well-controlled infections with undetectable virus levels may still be allowed (confirm with trial site)
  • You have uncontrolled kidney disease, pancreas disease, or liver disease (some liver conditions may still be allowed — confirm with trial site)
  • You have had another cancer in the last 2 years that needed treatment, unless it was an early-stage cancer treated with the aim of curing it (such as certain skin cancers or early bladder cancer) and you no longer need ongoing chemotherapy
  • You are currently taking certain medications including proton pump inhibitors (such as omeprazole), or certain drugs that strongly affect how the liver breaks down medications (confirm with trial site)
  • You are currently taking warfarin (Coumadin) or similar blood-thinning medications of the same type

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 26 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Daniel McCormick, 858 Therapeutics, Inc.

Phone: (858) 987-8380

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
858 Therapeutics, Inc.
Registry
ClinicalTrials.gov
Start date
13 May 2024
Est. completion
1 December 2026

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

To characterize the safety and tolerability of ETX-19477, the maximum tolerated dose (MTD) and/or RP2D of ETX-19477

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov